Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01227187 · ClinicalTrials.gov registry record · Phase 2
Safety and Dose Finding Study of Xigris in Hemodialysis Patients
A Phase 2 study of End Stage Renal Disease, sponsored by George Washington University.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01227187: Completed Phase 2 study of End Stage Renal Disease, sponsored by George Washington University.
NCT01227187 is a Phase 2 study of End Stage Renal Disease that has completed, run by George Washington University. The registered enrollment target is 12 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01227187, a Phase 2 study of End Stage Renal Disease, has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to assess the safety of Xigris (Drotrecogin alfa) as an anticoagulant at different dose levels during dialysis treatment in patients with End Stage Renal Disease (ESRD).
Primary Outcome
PTT level during a hemodialysis treatment will be used to assess the effectiveness of Xigris as an anticoagulant.
Conditions Studied
Interventions
- DRUG Drotrecogin alfa activated (Xigris)
Study Locations (1)
District of Columbia
- The George Washington University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT01227187 record still lists
NCT01227187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Drotrecogin alfa activated (Xigris) is the first listed.
NCT01227187 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01227187 about?
NCT01227187 is a clinical study titled "Safety and Dose Finding Study of Xigris in Hemodialysis Patients". The purpose of the study is to assess the safety of Xigris (Drotrecogin alfa) as an anticoagulant at different dose levels during dialysis treatment in patients with End Stage Renal Disease (ESRD).
What is the current status of trial NCT01227187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2008-10. Estimated completion is 2010-12.
What conditions does trial NCT01227187 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT01227187?
The interventions under investigation include: Drotrecogin alfa activated (Xigris) (DRUG).
Who is sponsoring clinical trial NCT01227187?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01227187 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01227187's enrollment target sits among peer trials
12 75th of 86 higher than 10 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
-
Safety and Efficacy of Empagliflozin in Hemodialysis
RECRUITING · Phase 2
-
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
RECRUITING · Phase 2
-
Communication During Hospitalization About Resuscitation Trial
ACTIVE NOT RECRUITING · Phase 2
-
The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients
COMPLETED · Phase 2
-
Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia